Ranolazine

Generic Name
Ranolazine
Brand Names
Aspruzyo Sprinkle, Ranexa, Ranexa (previously Latixa)
Drug Type
Small Molecule
Chemical Formula
C24H33N3O4
CAS Number
95635-55-5
Unique Ingredient Identifier
A6IEZ5M406
Background

Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drug...

Indication

Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.
...

Associated Conditions
Chronic Angina, Ventricular Arrhythmia
Associated Therapies
-
Clinical Trials
Related News

Targeting the Right Ventricle in Pulmonary Hypertension

Phase 4
Completed
Conditions
Pulmonary Hypertension
Interventions
Drug: Placebo
Drug: Ranolazine
First Posted Date
2013-04-24
Last Posted Date
2019-02-05
Lead Sponsor
University of Pennsylvania
Target Recruit Count
22
Registration Number
NCT01839110
Locations
🇺🇸

University of Maryland, Baltimore, Maryland, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pathophysiology and Prevention of Perioperative Myocardial Injury: A Prospective Randomized Controlled Trial

Phase 3
Conditions
Coronary Artery Disease,
Interventions
Drug: Ranolazine
First Posted Date
2013-03-14
Last Posted Date
2013-03-14
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
300
Registration Number
NCT01810796
Locations
🇮🇱

Hadassah - Hebrew University Medical Center, Jerusalem, Israel

Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy

First Posted Date
2013-03-05
Last Posted Date
2013-03-05
Lead Sponsor
Westside Medical Associates of Los Angeles
Target Recruit Count
30
Registration Number
NCT01804543
Locations
🇺🇸

Westside Medical Associates of Los Angeles, Beverly Hills, California, United States

Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia

First Posted Date
2013-02-22
Last Posted Date
2018-01-12
Lead Sponsor
Universitätsklinikum Hamburg-Eppendorf
Target Recruit Count
20
Registration Number
NCT01797484
Locations
🇩🇪

University Heart Center Hamburg Eppendorf, Hamburg, Germany

Ranolazine Cardioprotection in PCI

Phase 2
Terminated
Conditions
Acute Coronary Syndrome
Interventions
Drug: Placebo
Drug: Ranolazine
First Posted Date
2013-01-15
Last Posted Date
2017-09-14
Lead Sponsor
Harvey Hahn
Target Recruit Count
6
Registration Number
NCT01767987
Locations
🇺🇸

Kettering Medical Center, Kettering, Ohio, United States

A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension

First Posted Date
2012-12-31
Last Posted Date
2017-03-03
Lead Sponsor
University of Chicago
Target Recruit Count
12
Registration Number
NCT01757808
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD

First Posted Date
2012-12-21
Last Posted Date
2017-07-24
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
47
Registration Number
NCT01754259
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

Phase 2
Conditions
Long QT Syndrome Type 3
Interventions
Drug: Ranolazine
First Posted Date
2012-11-16
Last Posted Date
2015-03-26
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Target Recruit Count
10
Registration Number
NCT01728025
Locations
🇮🇱

Tel Aviv Medical Center, Tel Aviv, Israel

Ranolazine for the Treatment of Chest Pain in HCM Patients

Phase 4
Completed
Conditions
Hypertrophic Cardiomyopathy
Interventions
Drug: Ranolazine
First Posted Date
2012-11-06
Last Posted Date
2017-03-03
Lead Sponsor
Duke University
Target Recruit Count
14
Registration Number
NCT01721967
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)

Not Applicable
Terminated
Conditions
Cardiomyopathy
Interventions
Drug: Ranolazine
First Posted Date
2012-10-12
Last Posted Date
2020-02-18
Lead Sponsor
Cardiovascular Institute of the South Clinical Research Corporation
Target Recruit Count
14
Registration Number
NCT01705509
Locations
🇺🇸

Cardiovascular Institute of the South, Lafayette, Louisiana, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy